Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer
Authors:
Open Access
- 1 December 2013
- journal article
- research article
- Vol. 5 (6) , 783-789-789
Abstract
Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancerKeywords
This publication has 22 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancerMedical Oncology, 2013
- Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patientsMedical Oncology, 2013
- Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapyCancer Immunology, Immunotherapy, 2012
- Preoperative platelet count in predicting lymph node metastasis and prognosis in patients with non-small cell lung cancerNeoplasma, 2012
- Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancerClinical and Translational Oncology, 2011
- Immunity, Inflammation, and CancerCell, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Prognosis of Resected Ampullary Adenocarcinoma by Preoperative Serum CA19-9 Levels and Platelet-Lymphocyte RatioJournal of Gastrointestinal Surgery, 2008
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002